Invivyd, Inc. (NASDAQ:IVVD) Director Terrance Mcguire Sells 119,805 Shares

Invivyd, Inc. (NASDAQ:IVVD) Director Terrance Mcguire sold 119,805 shares of the company’s stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $0.42, for a total value of $50,318.10. Following the completion of the transaction, the director now owns 3,568,274 shares of the company’s stock, valued at approximately $1,498,675.08. This represents a 3.25 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Terrance Mcguire also recently made the following trade(s):

• On Thursday, December 26th, Terrance Mcguire sold 83,817 shares of Invivyd stock. The shares were sold at an average price of $0.54, for a total transaction of $45,261.18.
• On Monday, December 23rd, Terrance Mcguire sold 75,776 shares of Invivyd stock. The stock was sold at an average price of $0.45, for a total transaction of $34,099.20.
• On Wednesday, December 18th, Terrance Mcguire sold 74,764 shares of Invivyd stock. The shares were sold at an average price of $0.47, for a total transaction of $35,139.08.
• On Monday, December 16th, Terrance Mcguire sold 65,359 shares of Invivyd stock. The stock was sold at an average price of $0.47, for a total value of $30,718.73.
• On Wednesday, December 11th, Terrance Mcguire sold 160,400 shares of Invivyd stock. The shares were sold at an average price of $0.59, for a total value of $94,636.00.
• On Monday, December 9th, Terrance Mcguire sold 150,000 shares of Invivyd stock. The shares were sold at an average price of $0.61, for a total value of $91,500.00.

Invivyd Stock Performance

Shares of NASDAQ:IVVD opened at $0.51 on Friday. The company’s fifty day moving average is $0.73 and its two-hundred day moving average is $0.97. Invivyd, Inc. has a 1-year low of $0.40 and a 1-year high of $5.20. The stock has a market capitalization of $61.00 million, a price-to-earnings ratio of -0.26 and a beta of 0.53.

Institutional Investors Weigh In On Invivyd

Several institutional investors and hedge funds have recently bought and sold shares of the business. XTX Topco Ltd grew its holdings in shares of Invivyd by 68.1% during the second quarter. XTX Topco Ltd now owns 37,938 shares of the company’s stock valued at $42,000 after purchasing an additional 15,376 shares during the last quarter. SG Americas Securities LLC grew its stake in Invivyd by 198.6% during the 2nd quarter. SG Americas Securities LLC now owns 37,893 shares of the company’s stock worth $42,000 after buying an additional 25,201 shares during the last quarter. Proficio Capital Partners LLC acquired a new stake in Invivyd in the third quarter worth $27,000. Marshall Wace LLP lifted its stake in Invivyd by 4.2% in the second quarter. Marshall Wace LLP now owns 786,899 shares of the company’s stock valued at $866,000 after buying an additional 31,992 shares during the last quarter. Finally, State Street Corp lifted its stake in Invivyd by 3.7% in the third quarter. State Street Corp now owns 1,018,640 shares of the company’s stock valued at $1,039,000 after buying an additional 35,904 shares during the last quarter. Institutional investors and hedge funds own 70.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on IVVD shares. HC Wainwright dropped their price target on shares of Invivyd from $15.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, November 20th. Morgan Stanley dropped their target price on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a research report on Wednesday, November 20th. EF Hutton Acquisition Co. I raised shares of Invivyd to a “strong-buy” rating in a research report on Wednesday, October 30th. Finally, D. Boral Capital reissued a “buy” rating and issued a $9.00 price objective on shares of Invivyd in a report on Thursday, November 21st. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Invivyd has an average rating of “Buy” and a consensus price target of $7.89.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.